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Clinical Utility of C-Reactive
Protein Measured at Admission, Hospital
Discharge, and 1 Month Later to Predict
Outcome in Patients With Acute Coronary Disease
The RISCA (Recurrence and
Inflammation in the Acute Coronary Syndromes) Study
Peter Bogaty, MD,* Luce Boyer, RN,* Serge Simard, MSC,* Franz Dauwe, MD,† Robert Dupuis, MD,‡
Benoît Verret, MD,§ Thao Huynh, MD, Fernand Bertrand, BSC,* Gilles R. Dagenais, MD, FACC,*
James M. Brophy, MD, PHD, FACC¶
Quebec City, Chicoutimi, Thetford-Mines, Rivière-du-Loup, and Montreal, Quebec, Canada
Objectives This study was designed to prospectively determine, in patients with an acute coronary syndrome, whether the
inflammatory marker, C-reactive protein (CRP), measured at hospital admission, discharge, and 1 month later
has incremental value to predict outcomes at 1 year.
Background The clinical utility of CRP measurements in patients with acute coronary syndromes remains uncertain. Limita-
tions of previous studies have been retrospective design and incomplete adjustment for readily available clinical
prognosticators.
Methods The CRP marker was measured at admission, hospital discharge, and 1 month later in consecutive patients hos-
pitalized for acute coronary syndromes in 8 tertiary and secondary hospitals. The primary outcome was a com-
posite of death, nonfatal myocardial infarction (MI), and unstable angina (UA) with electrocardiogram (ECG)
changes at 1 year.
Results A total of 1,210 patients, age 62  12 years, 64% with acute myocardial infarction (MI) and 36% with unstable
angina (UA), were recruited. At 1 year, the primary outcome occurred in 142 patients (11.7%) and included 58
deaths (4.8%), 79 nonfatal MIs (6.5%), and 26 UA episodes with ECG changes (2.1%). The unadjusted odds ra-
tios (ORs) (95% confidence intervals) of CRP values at admission, hospital discharge, and 1 month later for the
occurrence of the primary outcome were 1.20 (1.06 to 1.36), 0.98 (0.85 to 1.14), and 1.23 (1.00 to 1.50), re-
spectively. After multivariate adjustment, ORs were 1.04 (0.91 to 1.20), 0.90 (0.77 to 1.06), and 1.12 (0.93 to
1.34), respectively. The individual components of the primary outcome were also not independently associated
with any of the 3 CRP measurements.
Conclusions The modest predictive ability of CRP following admission for an acute coronary syndrome disappeared after ad-
justing for common clinical variables. This large prospective study does not support the incremental value of
measuring CRP in this clinical setting. (J Am Coll Cardiol 2008;51:2339–46) © 2008 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.019m
a
o
M
p
S
atherosclerosis is considered an inflammatory disease, and its
cute manifestations of unstable angina (UA), myocardial
nfarction (MI), and sudden coronary death are associated with
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CRP and Acute Coronary Syndromes June 17, 2008:2339–46C-reactive protein (CRP) at pre-
sentation of an acute coronary syn-
drome may be associated with a
greater risk of poorer outcomes. It
is also plausible that the persis-
tence of more elevated blood in-
flammatory markers, presumed to
reflect a more active or smoldering
inflammatory atherosclerotic sub-
strate, may indicate which patients
re at greater risk of continuing and future coronary instability.
An important and elusive clinical challenge in patients
ith UA or MI is to better identify those patients who
ave a high risk of recurrence of acute coronary instabil-
ty. Some but not all recent studies have suggested that
he serum inflammatory marker, CRP, measured during
he acute episode, may provide this predictive informa-
ion (3,5,12–21). Limitations of these studies include
etrospective designs (5,13,14,21), small samples with
ow power (3,15,17,18,20), highly selective patient cohorts
5,12,14,16,21), and inadequate control of other prognosti-
ally important clinical variables (3,5,12–15,17,18,20,21).
s a result, despite the large number of clinical studies that
ave associated inflammatory markers, mostly CRP, with
rognosis in the acute coronary syndromes, it is still unclear
hether inflammatory markers are truly useful in the clinical
anagement of patients admitted with acute coronary
isease.
We therefore undertook this prospective multicenter
tudy in a relatively large and unselected group of patients
ospitalized with acute coronary syndromes to determine
hether CRP measured at any of 3 points—on admission,
t hospital discharge, and 1 month later—might reliably
redict those patients at risk of recurrent coronary instability
nd death and whether this information would be of
ncremental value to known and readily available clinical
rognosticators.
ethods
tudy population. Consecutive patients were recruited
rom 4 tertiary and 4 community hospitals, 7 in Quebec and
in New Brunswick, Canada. These hospitals were selected
ecause their clinical investigators were already collaborat-
ng in a clinical research network. Each hospital committee
n human research approved the study, and all patients gave
ritten informed consent.
To be eligible, patients had to have an urgent admission
ith a diagnosis of either acute MI or UA and had to be
ecruited into the study with a first study blood sample
btained within 24 h of symptom onset. Patients transferred
rom other hospitals were excluded.
The primary composite outcome was the first occurrence
f death, MI, or UA (see following discussion for complete
etails) at 1 year. The original protocol required a history of
Abbreviations
and Acronyms
CRP  C-reactive protein
ECG  electrocardiogram
MI  myocardial infarction
PCI  percutaneous
coronary intervention
UA  unstable anginaharacteristic chest discomfort or pain with an elevation of reatine kinase-myocardial band to 1.5 times the upper
ormal limit for the diagnosis of MI. The protocol was
ubsequently amended so that the diagnosis of MI required
nly characteristic chest pain and an abnormal troponin
levation diagnostic of MI. Thus, although the definition of
I changed during the study to include positive troponin
espite negative creatine kinase-myocardial band, this had a
eutral effect on primary composite outcome criteria be-
ause the latter change only reclassified some patients from
A to MI. The amended MI outcome definition was
etained for all analyses reported herein. A diagnosis of UA
equired either 1 episode lasting 10 min or 2 episodes
asting5 min of characteristic discomfort or pain at rest or
ith minimal exertion. This could be either new-onset
ngina or an abrupt and significant change in the pattern of
stablished angina and creatine kinase-myocardial band had
o be negative (1.5 times the upper normal limit). To
ncrease specificity, UA patients had to have at least 1 of the
ollowing features showing objective evidence of myocardial
schemia or high probability of coronary atherosclerosis:
lectrocardiogram (ECG) changes (0.5-mm ST-segment
epression or transient ST-segment elevation or 2-mm
-wave inversion in 2 contiguous leads); a cardiac tropo-
in I or T value in the positive range (subsequently
eclassified in the amended protocol as MI); history of MI
r coronary revascularization; previous coronary angiogram
ith at least 1 vessel showing 50% stenosis; previous
oninvasive test showing myocardial ischemia or evidence of
I; known peripheral arterial disease; known ischemic
erebrovascular disease; or presence of diabetes. A UA, for
he purposes of the primary outcome, was defined as a
haracteristic clinical syndrome requiring either significant
CG changes from previous ECG (1-mm ST-segment
epression in 2 contiguous leads or T-wave inversion 3
m in 3 contiguous leads) or a positive troponin value
the latter becoming a MI outcome, as previously discussed,
uring the course of the study). Secondary outcomes in-
luded singly and in various combinations death, cardiovas-
ular death, MI, and UA, the latter defined as previously as
ell as in 2 other less stringent ways: 1) a broad definition
f a characteristic chest pain syndrome requiring hospital-
zation (referred to as “soft UA”) and 2) the same as the soft
A plus requiring a supporting diagnostic test (referred to
s “test positive UA”).
Although there were no formal age limits or comorbidity
xclusion criteria, patients who could not comprehend the
onsent form or who were too ill to sign it or in whom a
eturn visit 1 month after hospital discharge was felt to be
roblematic were not recruited. A registry was kept of all
otentially eligible patients detailing reasons for exclusion.
Blood samples were taken: 1) acutely; 2) at hospital
ischarge; and 3) 1 month after hospital discharge. After
entrifugation, serum and plasma were distributed in ali-
uots, stored locally at 70°C and then transferred on dry
ce to the core laboratory. There, samples were stored at
80°C until analysis for CRP and cardiac troponin T (acute
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June 17, 2008:2339–46 CRP and Acute Coronary Syndromesample only). All measurements were performed in a single
atch. The CRP was measured with the N High-Sensitivity
RP mono assay using the BN ProsPec Nephelometer
Dade Behring, Deerfield, Illinois). Cardiac troponin T
as measured using a commercial assay (Roche Inc,
annheim, Germany) with a detection limit for myocardial
njury of 0.1 g/l.
All basic demographic and medical data, conventional
isk factors, clinical and paraclinical diagnostic and thera-
eutic information including recurrent ischemia, cardiac
unction, and use of invasive cardiac procedures were re-
orded in a comprehensive case report form. This informa-
ion was independently verified for consistency and, then in
ll cases, systematically reverified by on-site visits. Items in
he patient history such as previous heart failure or MI and
linical features such as heart failure during the index
ospitalization required firm documentation that fulfilled
redefined criteria. The ECG motivating the admission and
he final ECG before hospital discharge were obtained. The
CG analysis was performed at the core center. Follow-up
as ascertained 1 month after hospital discharge (at the
ime of blood sampling) and by telephone contact at 1 year,
btaining, where necessary, confirmatory hospital files. All
tudy outcomes were systematically recorded, as well as all
ther hospitalizations and their causes, cardiac catheteriza-
ions, and percutaneous and surgical revascularizations. All
vents were verified by on-site visits and examination of all
ecessary supporting documents. Finally, all prospective and
otential outcomes were centrally adjudicated indepen-
ently by 2 cardiologist investigators. In the case of a
isagreement, the final decision was reached by a third
ardiologist investigator.
tatistical analysis. Our sample size was calculated on an
nticipated 10% 1-year composite event rate. Therefore,
ecruitment of 1,200 patients would result in about 120
vents, providing sufficient precision for the numerous
equisite prediction parameters that would be included in
multivariate model (10 to 20 events per regression
erm). Continuous and dichotomous variables were ana-
yzed using Student t test and the chi-square test,
espectively. The cohort was divided into quartiles of
RP values obtained at each of the 3 points (admission,
ischarge, 1 month later) to obtain event curves from the
elson-Aalen estimator of the cumulative hazard rate.
he log-rank test and a test for trends were used to
ompare quartiles. For logistic regression analyses, the
election process was performed using univariate analysis
f each variable. Variables whose univariate test had a
value 0.20 were entered into a multivariate model.
he selected variables were analyzed using both stepwise
orward and backward approaches in the logistic regres-
ion model. Both approaches gave similar results. Anal-
ses of CRP were based on log-transformed values. The
esults were considered significant with p values 0.05.
he data were analyzed using the statistical packagerogram SAS version 9.1.3 (SAS Institute Inc., Cary,
orth Carolina).
esults
uring the period of recruitment (2001 to 2002), 2,672
atients were admitted with chest pain or discomfort in the
participating centers. This number excludes any patients
ho died in the emergency room before they could be
pproached for this study. A flow diagram depicts the
easons for exclusions in the constitution of the study cohort
Fig. 1). The clinical characteristics of the 1,210 patients of
he study (mean age 62  12 years, 75% males) are shown
n Table 1. About one-half of the patients had a previous
istory of coronary artery disease. The admission diagnosis
as MI in 772 (64%) patients with UA in the remainder.
uring initial hospitalization, there were 364 (30%) patients
ith ST-segment elevation MI of whom 77% received
eperfusion therapy (235 patients had fibrinolytic therapy
nd 45 patients had primary percutaneous coronary inter-
ention [PCI]). Coronary angiography was performed at
ome time during initial hospitalization in 678 (56%)
atients; PCI was performed in 437 (36%) patients and
oronary bypass surgery in 112 (9%) patients. Heart failure
ccurred in 109 (9%) patients.
2672 patients
admitted with chest pain*
Transferred from
another center (84)
Symptoms >24h
(269)
Live too far away for return
30-day visit (103)
Primary diagnosis unclear
or not an acute coronary
event (133)
Insufficient unstable angina
criteria (83)
Chest pain duration too
short (32)
Unable to recruit**
(off-hours, holidays) (124)
Cardiac condition too
precarious (50)
General condition
precludes return 30-day
visit (160)
1210 patients
in study cohort
Already recruited once in
same study (102)
Severe co-morbidity (137)
Patient refusal or
incomprehension (185)
Figure 1 Selection of Study Cohort
Flow diagram of screened patients admitted with chest pain, depicting reasons
for exclusions in selection of study cohort. *Excludes any patients who died
before they could be approached for this study. **In some centers.
(
1
f
r
e
y
c
t
S
m
h
i
s
l
c
a
1
v
w
i
9
a
[
r
a
p
m
w
p
p
s
c
w
q
i
t
(
q
0
o
a
(
p
t
d
C
w
a
a
s
d
s
l
o
r
d
r
c
r
t
j
C
T
m
s
r
C
p
C
s
t
C
C
C
i
2342 Bogaty et al. JACC Vol. 51, No. 24, 2008
CRP and Acute Coronary Syndromes June 17, 2008:2339–46The composite primary outcome occurred at 1 year in 142
11.7%) patients. Follow-up was obtained in 1,207 of the
,210 patients. Central adjudication of outcomes was per-
ormed by agreement of 2 investigators in all cases but 1 that
equired the intervention of a third investigator. Clinical
vents during initial hospitalization, at 1 month, and at 1
ear are detailed in Table 2. Univariate analyses of clinical
haracteristics in patients with and without occurrence of
he primary end point at 1 year are shown in Table 3.
ignificant univariate clinical predictors included age, fe-
ale gender, diabetes with and without insulin, history of
eart failure, history of MI, heart failure developing during
nitial hospitalization, admission heart rate 100/min, ST-
egment depression on admission, glycemia on admission,
eft ventricular ejection fraction 35%, and renal insuffi-
iency (creatinine clearance 50 ml/min).
All 1,210 patients had an admission CRP measurement;
hospital discharge CRP was obtained in 95.5% and a
-month CRP was obtained in 91.4% of patients. The CRP
alues at admission, discharge, and at 1 month in patients
ith and without the primary outcome at 1 year are shown
n Table 4 with corresponding unadjusted odds ratios and
5% confidence intervals (CIs). The CRP at admission and
t 1 month after hospital discharge had modest ability (1.20
95% CI 1.06 to 1.36] and 1.23 [95% CI 1.00 to 1.50],
espectively) to predict occurrence of the primary outcome
t 1 year. The CRP value at hospital discharge was not
redictive of the primary outcome at 1 year.
The CRP values at admission, hospital discharge, and 1
onth later of patients in whom the primary outcome as
ell as its individual components occurred compared with
atients without events are shown in Figure 2. Although
atients who were dying had higher CRP values than
urvivors, there was otherwise no difference in CRP con-
entrations between those with and without events. Results
ere similar when analyzed from the perspective of CRP
uartiles (data not shown). Admission CRP quartiles strat-
linical Characteristics of Study Group
Table 1 Clinical Characteristics of Study Group
Patients (n  1,210)
Age, yrs 62  12
Male 903 (75%)
Current smoker 368 (30%)
Arterial hypertension 616 (51%)
Diabetes 242 (20%)
Previous MI 341 (28%)
History of angina 451 (37%)
History of arterial (noncoronary) disease 247 (20%)
History of cerebrovascular disease 106 (9%)
History of heart failure 69 (6%)
Previous PCI 220 (18%)
Previous CABG 176 (15%)
First ever cardiac hospitalization 618 (51%)
ABG  coronary artery bypass graft; MI  myocardial infarction; PCI  percutaneous coronary
ntervention.fied risk of death at 1 year (p  0.001, log-rank test for
*rend) and drove the prediction of the primary outcome
p  0.01, log-rank test for trend). Admission CRP
uartiles did not predict the occurrence of MI at 1 year (p
.3, log-rank test for trend). Nor did the analysis of quartiles
f CRP at hospital discharge or 1 month later provide
dditional data in terms of the prediction of events at 1 year
data not shown).
The independent predictors for the occurrence of the
rimary outcome at 1 year were age, diabetes with insulin
herapy, a history of heart failure, and heart failure occurring
uring initial hospitalization (Table 5). The association of
RP with the occurrence of the primary outcome at 1 year
as no longer statistically significant after multivariate
djustment for these independent predictors (Table 5).
Independent predictors of death alone at 1 year were age,
history of heart failure, ST-segment depression at admis-
ion, glycemia at admission, and heart failure occurring
uring initial hospitalization. The ability of CRP at admis-
ion and at hospital discharge to predict death was again no
onger present after multivariate adjustment (Table 6). Use
f a dichotomous CRP value (3 mg/l signifying increased
isk) (18) at the 3 points did not change these findings.
We repeated all analyses substituting the broader UA
efinitions of soft UA and test positive UA. We then
epeated all analyses replacing death due to any cause with
ardiovascular death. None of these analyses yielded positive
esults for CRP after multivariate adjustment. Again, as for
he primary outcome, CRP at admission had modest unad-
usted predictive value for cardiovascular death at 1 year and
RP at 1 month had similar predictive value at 1 year.
hese results were not sustained after multivariate adjust-
ent. In all these analyses, CRP at hospital discharge
howed no predictive value. Finally, because recent angiog-
aphy and/or PCI and coronary bypass surgery could raise
RP measured at hospital discharge and confound inter-
retation, we examined the predictive ability of discharge
RP in those patients who did not have coronary bypass
urgery at any time before hospital discharge blood was
aken nor coronary angiography and/or PCI in the previous
linical Events on Follow-Up
Table 2 Clinical Events on Follow-Up
Initial
Hospitalization 1 Month 1 Year
Death 21 (1.7%) 33 (2.7%) 58 (4.8%)
Cardiovascular death 21 (1.7%) 32 (2.6%) 50 (4.1%)
MI (by troponin definition) 21 (1.7%) 39 (3.2%) 79 (6.5%)
UA (clinical diagnosis or soft UA)* — 45 (3.7%) 148 (12.2%)
UA (with supporting diagnostic
test)*
— 23 (1.9%) 75 (6.2%)
UA (with ECG changes)* — 6 (0.005%) 26 (2.2%)
Primary outcome (death, MI, or
UA with ECG changes)*
— 69 (5.7%) 142 (11.7%)
Any nonelective rehospitalization — 136 (11.4%) 413 (34.1%)Not counted during initial hospitalization.
ECG  electrocardiogram; UA  unstable angina; other abbreviation as in Table 1.
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June 17, 2008:2339–46 CRP and Acute Coronary Syndromes8 h. The univariate odds ratio of CRP at hospital discharge
o predict the primary outcome at 1 year in these 742
atients was 1.09 (95% CI 0.92 to 1.29; p  0.32). Results
ere unchanged if this analysis was enlarged to include patients
ho had coronary angiography but not PCI in the 48 h
receding the obtaining of the CRP hospital discharge sample.
iscussion
his multicenter prospective study was specifically designed
o determine whether there is clinical prognostic utility to
easuring CRP, which is the most studied marker of
nflammatory status, following an acute coronary episode.
e tested this “inflammatory hypothesis” at 3 points that
re potentially relevant on mechanistic grounds in addition
o being practical: acutely, at hospital discharge because this
s the time when patients are considered stabilized whatever
he length of the hospital stay, and 1 month later because
his is the time when persistent inflammation might augur
ecurrent instability as well as being generally within the
ime frame for an outpatient visit after the acute episode.
dditionally, CRP blood levels 1 month after hospital
ischarge might be less likely to be confounded by the
nflammatory contribution of myocardial necrosis if the
cute event was MI.
We found that CRP acutely and 1 month after hospital
ischarge had modest predictive value for the occurrence of
Univariate Analysis of Clinical Characteristics inWithout and With Occurrence of the Primary En
Table 3 Univariate Analysis of Clinical CharWithout and With Occurrence of the
No Prim
(n
Age, yrs 61
% males 81
History of myocardial infarction 28
History of heart failure 4
History of diabetes without insulin 14
History of diabetes with insulin 5
HR 100/min on first ECG 6
2 ST-segment on admission 14
1 ST-segment on admission 32
Admission glycemia, mmol/l 7
CK 1,000 U/l 24
Troponin diagnostic of myocardial injury 62
Ejection fraction 35% 4
Heart failure during index hospitalization 6
Creatinine clearance 50 ml/min 50
CK  creatine kinase; ECG  electrocardiogram; HR  heart rate.
CRP Values (mg/l; Mean  SD) in Relationto rimary End Point and Unadjusted Odds Ratio
Table 4 CRP Values (mg/l; Mean  SD) into Primary End Point and Unadjuste
Event at 1 Year
(n  142)
CRP at hospital admission 19.5 44.2
CRP at hospital discharge 18.8 28.7
CRP at 1 month after discharge 5.5 7.5CI  confidence interval; CRP  C-reactive protein.combined outcome of death, MI, and UA, and particularly
or death alone. This predictive value was no longer present
fter adjustment for readily available clinical prognostica-
ors. The CRP measured at hospital discharge showed no
redictive value. This latter “negative” result remained
nchanged when the analysis was restricted to patients who
id not have cardiac surgery or recent coronary angiography
nd/or PCI.
Our findings suggest that there is little if any incremental
linical utility to measuring CRP in acute coronary disease
t any of these 3 points. An examination of the predictive
bility of the individual components of the primary outcome
howed that it was the future occurrence of death, and not
I or UA, that was associated with higher CRP values at
dmission and at 1 month after hospital discharge. This
ould be explained by the stimulus of inflammatory cytokine
elease that occurs in confounding conditions such as heart
ailure as well as other comorbidities and organ dysfunctions
hat are associated with decreased survival (22–24). Other
tudies have also shown that CRP predicts death after an
cute coronary event but have not always adjusted for other
mportant and readily available predictors of increased
ortality (25–27). We found that age, diabetes, a history of
eart failure, and heart failure developing during the index
ospitalization were strong independent predictors of mor-
ality after an acute coronary syndrome. After adjustment
entsnt at 1 Year
istics in Patients
ary End Point at 1 Year
d Point
68)
Primary End Point
(n  142) p Value
1.4 68.2  11.5 0.001
%) 92 (64.8%) 0.004
%) 57 (40.1%) 0.0007
) 27 (19%) 0.0001
%) 31 (21.8%) 0.0001
) 21 (14.8%) 0.0001
) 21 (14.8%) 0.0003
) 38 (28.8%) 0.0001
%) 40 (28.2%) 0.6
.0 9.2  4.0 0.0001
%) 25 (17.6%) 0.12
%) 85 (60.7%) 0.6
) 20 (14.5%) 0.0001
) 42 (29.6%) 0.0001
%) 93 (65.5%) 0.0001
ion
ds Ratios
No Event at 1 Year
(n  1,068)
Unadjusted Odds Ratio
(95% CI)
13.6 26.1 1.20 (1.06–1.36)
22.1 33.4 0.98 (0.85–1.14)
4.9 10.1 1.23 (1.00–1.50)Patid Po
acter
Prim
ary En
 1,0
.6  1
1 (75.9
4 (26.6
2 (3.9%
0 (13.1
0 (4.7%
8 (6.4%
9 (14%
5 (30.4
.7  3
9 (23.5
1 (58.2
2 (4.0%
8 (6.4%
9 (47.8s
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CRP and Acute Coronary Syndromes June 17, 2008:2339–46or these factors, an independent contribution of CRP was
ot demonstrated.
Indeed, previous studies that have suggested that the
easurement of CRP has clinical utility in patients with
cute coronary syndromes have several limitations. They
ave involved small and/or selected (nonconsecutive) co-
orts (3,5,12–18,20,21,27). They have been retrospective
nd perhaps subject to publication bias (5,13,14,21,27).
hey have especially tended not to adequately adjust for
eadily available clinical parameters such as a history of heart
ailure, the presence of ECG changes, the presence or
egree of myocardial necrosis, the status of left ventric-
lar function and renal function, the presence of diabetes,
nd importantly the occurrence of heart failure during the
Figure 2 CRP Values in Patients With and Without Events
The C-reactive protein (CRP) values at admission, at hospital discharge, and at 1 m
primary outcome (death, myocardial infarction [MI] by troponin definition, or unstab
ndependent Predictors and Adjusted Odds Ratiosf CRP for the Occurrence of the Primary Outcomet 1 Year
Table 5
Independent Predictors and Adjusted Odds Ratios
of CRP for the Occurrence of the Primary Outcome
at 1 Year
Odds Ratio (95% CI) p Value
Age, yrs 1.04 (1.02–1.06) 0.001
Diabetes treated with insulin 2.58 (1.39–4.79) 0.02
History of heart failure 2.28 (1.25–4.18) 0.008
Heart failure during index hospitalization 1.75 (1.37–2.27) 0.001
CRP at hospital admission 1.04 (0.91–1.20) 0.56
CRP at hospital discharge 0.90 (0.77–1.06) 0.20
CRP at 1 month after discharge 1.12 (0.93–1.34) 0.24Abbreviations as in Table 4.ndex hospitalization (3,5,12–15,17,18,20,21,25–27). The
trengths of this prospective study in addressing the ques-
ion of whether there is predictive clinical utility in moni-
oring inflammatory status in patients with an acute coro-
ary syndrome are its design, carefully validated clinical
haracterization, relatively large sample size, the inclusion of
broad spectrum of patients afflicted with an acute coronary
yndrome, the examination of CRP at 3 pertinent points,
he consideration of a detailed combination of clinical
utcomes, and adjustment for relevant and readily available
linical prognosticators. The rates of invasive cardiac inter-
entions are also fairly comparable to those found in
ontemporary registry studies of patients with acute coro-
ary syndromes (28–30).
ndependent Predictors and Adjusted Oddsatios of CR for the Occurrence of Death at 1 Year
Table 6 Independent Predictors and Adjusted OddsRatios of CRP for the Occurrence of Death at 1 Year
Odds Ratio (95% CI) p Value
Age, yrs 1.1 (1.06–1.14) 0.001
History of heart failure 2.5 (1.2–5.4) 0.017
ST-segment depression on admission 2.6 (1.4–5.1) 0.004
Glycemia on admission 1.1 (1.0–1.2) 0.038
Heart failure during index hospitalization 5.4 (2.7–10.7) 0.001
CRP at hospital admission 1.1 (0.9–1.4) 0.4
CRP at hospital discharge 1.1 (0.8–1.4) 0.7
CRP at 1 month after discharge 1.4 (0.9–2.1) 0.14
after discharge in patients with and without occurrence of the
ina [UA] with electrocardiographic changes) and its individual components.onth
le angbbreviations as in Table 4.
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June 17, 2008:2339–46 CRP and Acute Coronary SyndromesThe notion that an inflammatory marker might predict
cute coronary recurrence has rested on the assumption
hat persistent inflammation, presumably both systemat-
cally and more specifically within the coronary arterial
irculation, would be associated with or might even
timulate coronary atherosclerotic plaque reactivation and
ecurrent coronary instability. The purest expression of
he latter is acute MI because it is clearly related to the
resence of occlusive thrombus on an active ruptured or
roded plaque. This pathophysiological link is less clear
or death or even for cardiovascular death where the
nderlying substrate is likely more heterogeneous because
ther immediate causes besides pro-inflammatory plaque
upture may be implicated such as arrhythmia, cardiac
ailure, and contributory comorbidity. The consistent link
ith inflammatory plaque rupture is also less clear for
A, because the latter can be a more benign and uncertain
iagnosis as well as a more heterogeneous entity that may
mplicate other destabilizing mechanisms such as increased
yocardial demand on a substrate of critically reduced
oronary arterial reserve. Therefore, the ideal mechanistic
terrain” on which to test the inflammatory hypothesis—
hat a raised CRP value at some point in the clinical
volution of patients hospitalized with an acute coronary
yndrome might be a harbinger for recurrent or persistent
cute coronary instability—is the subset of patients in whom
I occurs on follow-up. The finding of this study is
specially pertinent in this regard because no statistically
ignificant relation was found between CRP measured
cutely, at hospital discharge, or 1 month later and the
ccurrence of this clinical event. This suggests that the
echanism underlying the occurrence of acute MI in
atients previously hospitalized with an acute coronary
yndrome is more complex than the presence of a persistent
nd heightened—and measurable—inflammatory blood
rofile.
onclusions
n summary, this prospective study in a contemporary
nd broad spectrum of patients hospitalized with an acute
oronary syndrome has found that CRP measured acutely
nd 1 month after hospital discharge has modest, but not
ndependent, ability to predict death but does not predict
I or UA. The CRP measured at hospital discharge
ppears to have no predictive ability. This study does not
upport clinical use of CRP to aid clinical management in
atients hospitalized with an acute coronary syndrome.
he need for better predictive tools in these patients
emains an elusive clinical challenge.
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